Truist reiterates Hold on Hims and Hers stock ahead of earnings

Truist reiterated a Hold on Hims & Hers with an $18 price target, well below the $28.84 share price, while warning 2026 revenue may need to be revised lower due to lower AOV in branded GLP-1 memberships. The firm still expects Q1 revenue to beat the high end of guidance by $20 million to $25 million, and notes branded GLP-1 subscriber trends are ahead of expectations. The stock remains volatile after a 46% decline over the past year despite recent momentum.

Analysis

The market is still treating HIMS like a momentum consumer-health story, but the business is becoming a mix of high-growth subscription software economics layered on top of a pharmacy/membership model that is much less clean. The key second-order issue is mix: branded GLP-1 can lift user counts while compressing reported revenue intensity if medication costs remain off-P&L passthrough, which creates a setup where operating leverage and top-line optics decouple. That makes near-term guidance harder to read and raises the odds of a “beat on users, miss on revenue quality” reaction.

The competitive landscape is getting less forgiving. Bigger platforms with distribution breadth can undercut HIMS on customer acquisition, while pharma partnerships paradoxically help validate the category and lower the perceived moat around the front-end experience. If GLP-1 becomes a more standardized channel product, the durable value accrues to whoever controls supply, reimbursement access, and retention—not necessarily the best direct-to-consumer brand.

The near-term catalyst is not Q1 itself; it is the 2026 reset. If management trims revenue more than EBITDA, the stock can still de-rate because this name is currently priced for persistent hypergrowth, not margin normalization. The longer-duration risk is that higher branded mix crowds out the simpler, higher-visibility compounded economics, making consensus too aggressive on growth durability while understating the probability of multiple compression.

Contrarian view: the bearish read may be partially too mechanical. If branded GLP-1 subscriptions are growing faster than expected, the market may be overestimating the damage from lower AOV and underestimating retention and lifetime value expansion. That said, at this valuation, any hint that growth is becoming less incremental or more partner-dependent likely triggers a sharp reset before fundamentals fully roll over.

Key Decisions for Investors

• Short HIMS into the earnings window or via a post-print fade if guidance is cut; target a 15-25% downside move if revenue is revised more than EBITDA, with tight risk above the pre-earnings high.
• Use put spreads on HIMS for the next 4-6 weeks to express a de-rating view while limiting premium bleed; best asymmetric setup if management validates the revenue mix concern but keeps EBITDA intact.
• Pair trade: long NVO, short HIMS over 1-3 months as a relative-value hedge on category normalization; thesis is that the incumbent supply owner is better positioned if branded GLP-1 volumes stay strong.
• For existing longs, trim into any post-earnings bounce and reassess only if management proves branded GLP-1 can sustain AOV without a step-down in margin quality.